Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Mylan Unit Ups Stake in China Subsidiary

publication date: Feb 11, 2008

Matrix Laboratories of India has increased its ownership of the China-based Mchem group of companies, which produce intermediates, active pharmaceutical ingredients and finished dose products. In 2005, Matrix bought a 60% stake in Mchem, but it will now bring its ownership to 97%. In 2005, at the time of the Matrix purchase, Mchem was described as having $35 million in annual revenues. In August 2006, Mylan Labs (NYSE: MYL) paid $736 million to acquire a 71.5% stake in the parent, Matrix Labs, which is listed on the Bombay exchange.  More details...

Stock Symbol: (NYSE:MYL)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here